Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP829859.RAFn_S8nyc-2D8nBCMaHkfrxvIgtwy-w-LCW5xNVSFnv4130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP829859.RAFn_S8nyc-2D8nBCMaHkfrxvIgtwy-w-LCW5xNVSFnv4130_assertion type Assertion NP829859.RAFn_S8nyc-2D8nBCMaHkfrxvIgtwy-w-LCW5xNVSFnv4130_head.
- NP829859.RAFn_S8nyc-2D8nBCMaHkfrxvIgtwy-w-LCW5xNVSFnv4130_assertion wasGeneratedBy ECO_0000203 NP829859.RAFn_S8nyc-2D8nBCMaHkfrxvIgtwy-w-LCW5xNVSFnv4130_provenance.
- NP829859.RAFn_S8nyc-2D8nBCMaHkfrxvIgtwy-w-LCW5xNVSFnv4130_assertion wasDerivedFrom befree-20140225 NP829859.RAFn_S8nyc-2D8nBCMaHkfrxvIgtwy-w-LCW5xNVSFnv4130_provenance.
- NP829859.RAFn_S8nyc-2D8nBCMaHkfrxvIgtwy-w-LCW5xNVSFnv4130_assertion SIO_000772 20721741 NP829859.RAFn_S8nyc-2D8nBCMaHkfrxvIgtwy-w-LCW5xNVSFnv4130_provenance.
- NP829859.RAFn_S8nyc-2D8nBCMaHkfrxvIgtwy-w-LCW5xNVSFnv4130_assertion evidence source_evidence_literature NP829859.RAFn_S8nyc-2D8nBCMaHkfrxvIgtwy-w-LCW5xNVSFnv4130_provenance.
- NP829859.RAFn_S8nyc-2D8nBCMaHkfrxvIgtwy-w-LCW5xNVSFnv4130_assertion description "[Specifically, in familial cancer syndromes, DHPLC has been reported as a genetic screening tool for the risk of developing breast and ovarian cancer (BRCA1), von Hippel Lindau disease (VHL), Cowden syndrome (PTEN), and Multiple Endocrine Neoplasia types 1 and 2 (MEN1 and RET).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP829859.RAFn_S8nyc-2D8nBCMaHkfrxvIgtwy-w-LCW5xNVSFnv4130_provenance.